Innoviva, Inc. Common Stock INVA
i
Market dataready · fetched 2026-11-11T14:55:23.947Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:54:26.211127865Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T14:55:22.908802+00:00
Innoviva, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 16.32 | 59.5% | 16.2% | |||
| 25Δ | 20.65 | 33.7% | 11.0% | 16.82 | 62.5% | 14.4% |
| 30Δ | 19.87 | 29.9% | 7.5% | 17.33 | 65.4% | 12.6% |
| 35Δ | 19.55 | 35.9% | 7.4% | 17.71 | 63.3% | 11.1% |
| 40Δ | 19.24 | 41.8% | 7.2% | 18.02 | 58.6% | 9.7% |
| 45Δ | 18.92 | 47.7% | 7.0% | 18.34 | 53.8% | 8.4% |
| 50Δ | 18.60 | 53.7% | 6.8% | 18.65 | 49.1% | 7.0% |
| 55Δ | 18.28 | 59.6% | 6.6% | 18.97 | 44.3% | 5.6% |
| 60Δ | 17.96 | 65.5% | 6.4% | 19.28 | 39.5% | 4.3% |
| 65Δ | 17.64 | 71.5% | 6.2% | 19.60 | 34.8% | 2.9% |
| 70Δ | 17.20 | 72.7% | 5.6% | 19.92 | 30.0% | 1.5% |
| 75Δ | 16.64 | 70.1% | 4.5% | |||
| 80Δ | 16.08 | 67.5% | 3.4% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.32
- IV
- 59.5%
- B/E move
- 16.2%
25Δ
- Pseudo strike
- 20.65
- IV
- 33.7%
- B/E move
- 11.0%
- Pseudo strike
- 16.82
- IV
- 62.5%
- B/E move
- 14.4%
30Δ
- Pseudo strike
- 19.87
- IV
- 29.9%
- B/E move
- 7.5%
- Pseudo strike
- 17.33
- IV
- 65.4%
- B/E move
- 12.6%
35Δ
- Pseudo strike
- 19.55
- IV
- 35.9%
- B/E move
- 7.4%
- Pseudo strike
- 17.71
- IV
- 63.3%
- B/E move
- 11.1%
40Δ
- Pseudo strike
- 19.24
- IV
- 41.8%
- B/E move
- 7.2%
- Pseudo strike
- 18.02
- IV
- 58.6%
- B/E move
- 9.7%
45Δ
- Pseudo strike
- 18.92
- IV
- 47.7%
- B/E move
- 7.0%
- Pseudo strike
- 18.34
- IV
- 53.8%
- B/E move
- 8.4%
50Δ
- Pseudo strike
- 18.60
- IV
- 53.7%
- B/E move
- 6.8%
- Pseudo strike
- 18.65
- IV
- 49.1%
- B/E move
- 7.0%
55Δ
- Pseudo strike
- 18.28
- IV
- 59.6%
- B/E move
- 6.6%
- Pseudo strike
- 18.97
- IV
- 44.3%
- B/E move
- 5.6%
60Δ
- Pseudo strike
- 17.96
- IV
- 65.5%
- B/E move
- 6.4%
- Pseudo strike
- 19.28
- IV
- 39.5%
- B/E move
- 4.3%
65Δ
- Pseudo strike
- 17.64
- IV
- 71.5%
- B/E move
- 6.2%
- Pseudo strike
- 19.60
- IV
- 34.8%
- B/E move
- 2.9%
70Δ
- Pseudo strike
- 17.20
- IV
- 72.7%
- B/E move
- 5.6%
- Pseudo strike
- 19.92
- IV
- 30.0%
- B/E move
- 1.5%
75Δ
- Pseudo strike
- 16.64
- IV
- 70.1%
- B/E move
- 4.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 16.08
- IV
- 67.5%
- B/E move
- 3.4%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 73.66% | |
| 101.97% | |
| 43.64% | |
| 68.47% | |
| 62.08% | |
| 86.39% | |
| 114.02% | |
| 126.22% | |
| 42.18% | |
| 46.09% | |
| 54.65% | |
| 56.68% | |
| 49.97% | |
| 61.66% | |
| 58.45% | |
| 54.22% | |
| 129.28% | |
| 100.34% | |
| 103.16% | |
| 43.93% | |
| 36.23% | |
| 64.11% | |
| 55.70% | |
| 48.62% | |
| 50.50% | |
| 60.39% | |
| 70.93% | |
| 49.91% | |
| 61.42% |
Biotechnology
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
More →IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's…
More →IPSC
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging…
More →IRD
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. Utilizing cutting-edge…
More →IRON
Description unavailable
More →IVA
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH),…
More →